AstraZeneca PLC (AZN)

Currency in GBP
14,112.0
+130.0(+0.93%)
Real-time Data·
Advertisement
AZN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
13,964.014,148.0
52 wk Range
11,404.015,730.0
Key Statistics
Bid/Ask
14,112.00 / 14,116.00
Prev. Close
13,982
Open
14,056
Day's Range
13,964-14,148
52 wk Range
11,404-15,730
Volume
256.15K
Average Volume (3m)
2.75M
1-Year Change
4.3009%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AZN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
16,317.7
Upside
+15.63%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high P/E ratio relative to near-term earnings growth

AstraZeneca PLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Analyst Ratings

19 Buy
5 Hold
0 Sell
Ratings:
24 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 16,317.7
(+15.63% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Deutsche Bank
Hold120.00-14.98%117.00Maintain06/11/2026
RBC Capital
Buy152.50+8.04%145.00Maintain02/11/2026
UBS
Buy160.00+13.36%152.00Maintain02/11/2026
Barclays
Buy170.00+20.44%160.00Maintain02/11/2026
Citi
Buy189.00+33.90%186.00Maintain02/11/2026

AstraZeneca PLC Earnings Call Summary for Q3/2026

  • AstraZeneca Q3 2026 EPS of $2.79 beat estimates by 7.72%; revenue of $16.21B topped forecasts, driving shares up 6.96% to $13,960 premarket.
  • Oncology revenue surged 17% in Q3, led by Tagrisso and Enhertu, offsetting 18% decline in cardiovascular segment due to Farxiga patent loss.
  • Company launched $2B restructuring program targeting $1.5B in annual pre-tax savings to be reinvested in pipeline development and launches.
  • Management reiterated full-year guidance of mid-to-high single-digit revenue growth and low double-digit EPS growth for 2026.
  • Executives forecast over 20 high-value trial readouts in 2027, including nine potential new medicines with 12 programs exceeding $5B peak revenue potential.
Last Updated: 01/11/2026, 09:14
Read Full Transcript

Earnings

Latest Release
30/10/2026
EPS / Forecast
2.79 / 2.59
Revenue / Forecast
16.21B / 16.04B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 5.37
Dividend Yield
1.71%
Industry Median 3.24%
Annualised payout
239.00
Paid unevenly
5-Years Growth
+2.90%
Growth Streak

Compare AZN to Peers and Sector

Metrics to compare
AZN
Peers
Sector
Relationship
P/E Ratio
26.0x26.4x−0.2x
PEG Ratio
1.500.400.00
Price/Book
5.5x3.6x2.6x
Price / LTM Sales
4.6x3.5x2.8x
Upside (Analyst Target)
15.6%2.2%65.0%
Fair Value Upside
Unlock10.7%9.5%Unlock

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, USA, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra, Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is based in Cambridge, the United Kingdom.

Employees
96100

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
658.73M42.47%92.10B
Other Institutional Investors
511.24M32.96%71.48B
Public Companies & Retail Investors
381.06M24.57%53.28B
Total
1.55B100.00%216.86B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.8.85%137,288,69719,195,706
Vanguard Capital Management, LLC3.78%58,677,2758,204,257

People Also Watch

1,939.02
GSK
+1.44%
1,495.16
ASML
-0.13%
156.76
MRVL
-4.68%
162.85
NVDA
-2.01%
1,443.50
LLY
+1.14%

FAQ

What Is the AstraZeneca (London: AZN) Share Price Today?

The AstraZeneca stock price today is 14,112.0 GBP.

What Stock Exchange Does AstraZeneca (AZN) Trade On?

AstraZeneca is listed and trades on the London Stock Exchange.

What Is the Ticker (Stock Symbol) for AstraZeneca?

The stock symbol (also called a 'ticker') for AstraZeneca is "AZN."

Does AstraZeneca Pay Dividends? What’s The Current AZN Dividend Yield?

Yes, AZN Pays Dividends to its Shareholders. The current AstraZeneca dividend yield is 1.7%%.

What Is the Current AstraZeneca Market Capitalisation?

As of today, AstraZeneca (London: AZN) market cap is 219.1B GBP.

What Is AstraZeneca's (AZN) Earnings Per Share (TTM)?

The AstraZeneca EPS is currently 5.37 (Trailing Twelve Months).

When Is the Next AstraZeneca Earnings Date?

AstraZeneca's next earnings report will be released on 11/02/2027.

Is AZN a Buy or Sell From a Technical Analyst Perspective?

Based on today's AstraZeneca moving averages and other technical indicators, the daily buy/sell signal for AZN stock is Strong Buy.

How Many Times Has AstraZeneca Stock Split?

AstraZeneca has split 0 times. (See the AZN stock split history page for full effective split date and price information.)

How Many Employees Does AstraZeneca Have?

AstraZeneca has 96100 employees, based on their latest Companies House report.

What is the current trading status of AstraZeneca (London: AZN)?

As of 16/11/2026, AstraZeneca (AZN) is trading at a share price of 14,112.0 GBP, with a previous close of 13,982.0 GBP. The stock has fluctuated within a day range of 13,964.0 GBP to 14,148.0 GBP, while its 52-week range spans from 11,404.0 GBP to 15,730.0 GBP.

What Is AstraZeneca (AZN) Price Target According to Analysts?

The average 12-month price target for AstraZeneca is 16,317.7 GBP, with a high estimate of 20824.75242277 GBP and a low estimate of 12142.20245306 GBP. 19 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +15.63% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.